Seeking Alpha

Oragenics and Intrexon announce encouraging results in lantibiotic testing

  • Oragenics (OGEN +1.3%) and recent IPO Intrexon (XON -2%) say that collaborative experiments demonstrate a genetically-modified host can be engineered to produce improved titers of OGEN's lead compound MU1140, progressing towards the commercial production of lantibiotics, a novel-class of broad-spectrum antibiotics.
  • The collaboration also uncovered two new methods of purifying its lead compound resulting in higher purity and yields of MU1140.
  • OGEN and XON entered into an Exclusive Channel Collaboration agreement to develop and commercialize lantibiotics for the treatment of infectious diseases in June 2012.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: